HEADER TRANSFERASE 11-JAN-07 2OIQ TITLE CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE TITLE 2 CANCER DRUG IMATINIB. COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: KINASE DOMAIN; COMPND 5 SYNONYM: P60-SRC, C- SRC, PP60C-SRC; COMPND 6 EC: 2.7.10.2; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: GALLUS GALLUS; SOURCE 3 ORGANISM_COMMON: CHICKEN; SOURCE 4 ORGANISM_TAXID: 9031; SOURCE 5 GENE: SRC; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21DE3; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28 KEYWDS SRC, KINASE, IMATINIB, INACTIVE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR M.A.SEELIGER,B.NAGAR,F.FRANK,X.CAO,M.N.HENDERSON,J.KURIYAN REVDAT 6 30-AUG-23 2OIQ 1 REMARK HETSYN REVDAT 5 15-APR-20 2OIQ 1 REMARK SEQADV REVDAT 4 13-JUL-11 2OIQ 1 VERSN REVDAT 3 24-FEB-09 2OIQ 1 VERSN REVDAT 2 27-MAR-07 2OIQ 1 JRNL REVDAT 1 20-MAR-07 2OIQ 0 JRNL AUTH M.A.SEELIGER,B.NAGAR,F.FRANK,X.CAO,M.N.HENDERSON,J.KURIYAN JRNL TITL C-SRC BINDS TO THE CANCER DRUG IMATINIB WITH AN INACTIVE JRNL TITL 2 ABL/C-KIT CONFORMATION AND A DISTRIBUTED THERMODYNAMIC JRNL TITL 3 PENALTY. JRNL REF STRUCTURE V. 15 299 2007 JRNL REFN ISSN 0969-2126 JRNL PMID 17355866 JRNL DOI 10.1016/J.STR.2007.01.015 REMARK 2 REMARK 2 RESOLUTION. 2.07 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 93.5 REMARK 3 NUMBER OF REFLECTIONS : 43035 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.227 REMARK 3 FREE R VALUE : 0.263 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 2193 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.07 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.20 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 81.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.3000 REMARK 3 BIN FREE R VALUE : 0.3500 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 330 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4261 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 49 REMARK 3 SOLVENT ATOMS : 250 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 21.90 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 42.40 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -5.12000 REMARK 3 B22 (A**2) : -4.07000 REMARK 3 B33 (A**2) : 9.20000 REMARK 3 B12 (A**2) : -3.02000 REMARK 3 B13 (A**2) : -1.13000 REMARK 3 B23 (A**2) : 1.72000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.29 REMARK 3 ESD FROM SIGMAA (A) : 0.25 REMARK 3 LOW RESOLUTION CUTOFF (A) : 50.0 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.33 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.29 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.00 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.790 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2OIQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 17-JAN-07. REMARK 100 THE DEPOSITION ID IS D_1000041185. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-JAN-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 8.2.1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : KOHZU: DOUBLE CRYSTAL SI(111) REMARK 200 OPTICS : KOHZU: DOUBLE CRYSTAL SI(111) REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 48106 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.0 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.11500 REMARK 200 FOR THE DATA SET : 10.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 83.5 REMARK 200 DATA REDUNDANCY IN SHELL : 2.40 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.42400 REMARK 200 FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 2SRC REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 58.67 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.98 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M MES, 4% GLYCEROL, 12% PEG 4000, REMARK 280 50 MM SODIUM ACETATE, PH 6.5, VAPOR DIFFUSION, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 248 REMARK 465 HIS A 249 REMARK 465 MET A 250 REMARK 465 GLN A 251 REMARK 465 THR A 252 REMARK 465 GLN A 253 REMARK 465 GLY A 254 REMARK 465 LEU A 255 REMARK 465 ALA A 408 REMARK 465 ARG A 409 REMARK 465 LEU A 410 REMARK 465 ILE A 411 REMARK 465 GLU A 412 REMARK 465 ASP A 413 REMARK 465 ASN A 414 REMARK 465 GLU A 415 REMARK 465 TYR A 416 REMARK 465 THR A 417 REMARK 465 ALA A 418 REMARK 465 ARG A 419 REMARK 465 GLN A 420 REMARK 465 GLY B 248 REMARK 465 HIS B 249 REMARK 465 MET B 250 REMARK 465 GLN B 251 REMARK 465 THR B 252 REMARK 465 GLN B 253 REMARK 465 GLY B 254 REMARK 465 LEU B 255 REMARK 465 ALA B 256 REMARK 465 LYS B 257 REMARK 465 ASP B 413 REMARK 465 ASN B 414 REMARK 465 GLU B 415 REMARK 465 TYR B 416 REMARK 465 THR B 417 REMARK 465 ALA B 418 REMARK 465 ARG B 419 REMARK 465 GLN B 420 REMARK 465 GLY B 421 REMARK 465 ALA B 422 REMARK 465 LYS B 423 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 289 -34.73 -133.71 REMARK 500 SER A 342 -31.72 -36.82 REMARK 500 HIS A 384 -60.46 -90.91 REMARK 500 ARG A 385 -14.30 88.42 REMARK 500 ASP A 386 38.07 -145.29 REMARK 500 GLU A 486 -0.41 68.67 REMARK 500 ARG B 268 84.82 -150.83 REMARK 500 GLU B 270 -98.32 -111.98 REMARK 500 MET B 283 77.02 -114.11 REMARK 500 THR B 289 -28.22 -142.25 REMARK 500 PRO B 299 -60.31 -14.73 REMARK 500 SER B 330 47.80 -71.22 REMARK 500 ARG B 385 -5.91 77.34 REMARK 500 ASP B 386 38.38 -145.07 REMARK 500 ASP B 404 70.38 61.81 REMARK 500 PRO B 425 99.35 -58.92 REMARK 500 GLU B 486 -1.68 70.97 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE STI A 1001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 1002 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 1003 DBREF 2OIQ A 251 533 UNP P00523 SRC_CHICK 250 532 DBREF 2OIQ B 251 533 UNP P00523 SRC_CHICK 250 532 SEQADV 2OIQ GLY A 248 UNP P00523 CLONING ARTIFACT SEQADV 2OIQ HIS A 249 UNP P00523 CLONING ARTIFACT SEQADV 2OIQ MET A 250 UNP P00523 INITIATING METHIONINE SEQADV 2OIQ GLY B 248 UNP P00523 CLONING ARTIFACT SEQADV 2OIQ HIS B 249 UNP P00523 CLONING ARTIFACT SEQADV 2OIQ MET B 250 UNP P00523 INITIATING METHIONINE SEQRES 1 A 286 GLY HIS MET GLN THR GLN GLY LEU ALA LYS ASP ALA TRP SEQRES 2 A 286 GLU ILE PRO ARG GLU SER LEU ARG LEU GLU VAL LYS LEU SEQRES 3 A 286 GLY GLN GLY CYS PHE GLY GLU VAL TRP MET GLY THR TRP SEQRES 4 A 286 ASN GLY THR THR ARG VAL ALA ILE LYS THR LEU LYS PRO SEQRES 5 A 286 GLY THR MET SER PRO GLU ALA PHE LEU GLN GLU ALA GLN SEQRES 6 A 286 VAL MET LYS LYS LEU ARG HIS GLU LYS LEU VAL GLN LEU SEQRES 7 A 286 TYR ALA VAL VAL SER GLU GLU PRO ILE TYR ILE VAL THR SEQRES 8 A 286 GLU TYR MET SER LYS GLY SER LEU LEU ASP PHE LEU LYS SEQRES 9 A 286 GLY GLU MET GLY LYS TYR LEU ARG LEU PRO GLN LEU VAL SEQRES 10 A 286 ASP MET ALA ALA GLN ILE ALA SER GLY MET ALA TYR VAL SEQRES 11 A 286 GLU ARG MET ASN TYR VAL HIS ARG ASP LEU ARG ALA ALA SEQRES 12 A 286 ASN ILE LEU VAL GLY GLU ASN LEU VAL CYS LYS VAL ALA SEQRES 13 A 286 ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP ASN GLU TYR SEQRES 14 A 286 THR ALA ARG GLN GLY ALA LYS PHE PRO ILE LYS TRP THR SEQRES 15 A 286 ALA PRO GLU ALA ALA LEU TYR GLY ARG PHE THR ILE LYS SEQRES 16 A 286 SER ASP VAL TRP SER PHE GLY ILE LEU LEU THR GLU LEU SEQRES 17 A 286 THR THR LYS GLY ARG VAL PRO TYR PRO GLY MET VAL ASN SEQRES 18 A 286 ARG GLU VAL LEU ASP GLN VAL GLU ARG GLY TYR ARG MET SEQRES 19 A 286 PRO CYS PRO PRO GLU CYS PRO GLU SER LEU HIS ASP LEU SEQRES 20 A 286 MET CYS GLN CYS TRP ARG LYS ASP PRO GLU GLU ARG PRO SEQRES 21 A 286 THR PHE GLU TYR LEU GLN ALA PHE LEU GLU ASP TYR PHE SEQRES 22 A 286 THR SER THR GLU PRO GLN TYR GLN PRO GLY GLU ASN LEU SEQRES 1 B 286 GLY HIS MET GLN THR GLN GLY LEU ALA LYS ASP ALA TRP SEQRES 2 B 286 GLU ILE PRO ARG GLU SER LEU ARG LEU GLU VAL LYS LEU SEQRES 3 B 286 GLY GLN GLY CYS PHE GLY GLU VAL TRP MET GLY THR TRP SEQRES 4 B 286 ASN GLY THR THR ARG VAL ALA ILE LYS THR LEU LYS PRO SEQRES 5 B 286 GLY THR MET SER PRO GLU ALA PHE LEU GLN GLU ALA GLN SEQRES 6 B 286 VAL MET LYS LYS LEU ARG HIS GLU LYS LEU VAL GLN LEU SEQRES 7 B 286 TYR ALA VAL VAL SER GLU GLU PRO ILE TYR ILE VAL THR SEQRES 8 B 286 GLU TYR MET SER LYS GLY SER LEU LEU ASP PHE LEU LYS SEQRES 9 B 286 GLY GLU MET GLY LYS TYR LEU ARG LEU PRO GLN LEU VAL SEQRES 10 B 286 ASP MET ALA ALA GLN ILE ALA SER GLY MET ALA TYR VAL SEQRES 11 B 286 GLU ARG MET ASN TYR VAL HIS ARG ASP LEU ARG ALA ALA SEQRES 12 B 286 ASN ILE LEU VAL GLY GLU ASN LEU VAL CYS LYS VAL ALA SEQRES 13 B 286 ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP ASN GLU TYR SEQRES 14 B 286 THR ALA ARG GLN GLY ALA LYS PHE PRO ILE LYS TRP THR SEQRES 15 B 286 ALA PRO GLU ALA ALA LEU TYR GLY ARG PHE THR ILE LYS SEQRES 16 B 286 SER ASP VAL TRP SER PHE GLY ILE LEU LEU THR GLU LEU SEQRES 17 B 286 THR THR LYS GLY ARG VAL PRO TYR PRO GLY MET VAL ASN SEQRES 18 B 286 ARG GLU VAL LEU ASP GLN VAL GLU ARG GLY TYR ARG MET SEQRES 19 B 286 PRO CYS PRO PRO GLU CYS PRO GLU SER LEU HIS ASP LEU SEQRES 20 B 286 MET CYS GLN CYS TRP ARG LYS ASP PRO GLU GLU ARG PRO SEQRES 21 B 286 THR PHE GLU TYR LEU GLN ALA PHE LEU GLU ASP TYR PHE SEQRES 22 B 286 THR SER THR GLU PRO GLN TYR GLN PRO GLY GLU ASN LEU HET STI A1001 37 HET GOL A1002 6 HET GOL A1003 6 HETNAM STI 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4- HETNAM 2 STI PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE HETNAM GOL GLYCEROL HETSYN STI STI-571; IMATINIB HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 3 STI C29 H31 N7 O FORMUL 4 GOL 2(C3 H8 O3) FORMUL 6 HOH *250(H2 O) HELIX 1 1 PRO A 263 GLU A 265 5 3 HELIX 2 2 SER A 303 LEU A 317 1 15 HELIX 3 3 SER A 345 GLY A 352 1 8 HELIX 4 4 ARG A 359 MET A 380 1 22 HELIX 5 5 ARG A 388 ALA A 390 5 3 HELIX 6 6 GLU A 396 LEU A 398 5 3 HELIX 7 7 PRO A 425 THR A 429 5 5 HELIX 8 8 ALA A 430 GLY A 437 1 8 HELIX 9 9 THR A 440 THR A 457 1 18 HELIX 10 10 VAL A 467 ARG A 477 1 11 HELIX 11 11 PRO A 488 TRP A 499 1 12 HELIX 12 12 THR A 508 ASP A 518 1 11 HELIX 13 13 ASP A 518 THR A 523 1 6 HELIX 14 14 PRO B 263 GLU B 265 5 3 HELIX 15 15 SER B 303 LEU B 308 1 6 HELIX 16 16 LEU B 308 LEU B 317 1 10 HELIX 17 17 SER B 345 GLY B 352 1 8 HELIX 18 18 GLU B 353 LEU B 358 5 6 HELIX 19 19 ARG B 359 MET B 380 1 22 HELIX 20 20 ARG B 388 ALA B 390 5 3 HELIX 21 21 GLU B 396 LEU B 398 5 3 HELIX 22 22 ALA B 430 GLY B 437 1 8 HELIX 23 23 THR B 440 THR B 457 1 18 HELIX 24 24 VAL B 467 ARG B 477 1 11 HELIX 25 25 PRO B 488 TRP B 499 1 12 HELIX 26 26 ASP B 502 ARG B 506 5 5 HELIX 27 27 THR B 508 ASP B 518 1 11 HELIX 28 28 ASP B 518 THR B 523 1 6 SHEET 1 A 5 LEU A 267 GLN A 275 0 SHEET 2 A 5 GLU A 280 TRP A 286 -1 O VAL A 281 N LEU A 273 SHEET 3 A 5 THR A 290 THR A 296 -1 O THR A 296 N GLU A 280 SHEET 4 A 5 TYR A 335 GLU A 339 -1 O ILE A 336 N LYS A 295 SHEET 5 A 5 LEU A 325 VAL A 329 -1 N TYR A 326 O VAL A 337 SHEET 1 B 2 ILE A 392 VAL A 394 0 SHEET 2 B 2 CYS A 400 VAL A 402 -1 O LYS A 401 N LEU A 393 SHEET 1 C 3 LEU B 267 GLN B 275 0 SHEET 2 C 3 GLU B 280 TRP B 286 -1 O VAL B 281 N LEU B 273 SHEET 3 C 3 THR B 290 ARG B 291 -1 O THR B 290 N TRP B 286 SHEET 1 D 5 LEU B 267 GLN B 275 0 SHEET 2 D 5 GLU B 280 TRP B 286 -1 O VAL B 281 N LEU B 273 SHEET 3 D 5 ALA B 293 THR B 296 -1 O ILE B 294 N TRP B 282 SHEET 4 D 5 TYR B 335 THR B 338 -1 O THR B 338 N ALA B 293 SHEET 5 D 5 LEU B 325 VAL B 329 -1 N TYR B 326 O VAL B 337 SHEET 1 E 2 TYR B 382 VAL B 383 0 SHEET 2 E 2 ARG B 409 LEU B 410 -1 O ARG B 409 N VAL B 383 SHEET 1 F 2 ILE B 392 VAL B 394 0 SHEET 2 F 2 CYS B 400 VAL B 402 -1 O LYS B 401 N LEU B 393 CISPEP 1 GLU A 332 PRO A 333 0 -0.08 CISPEP 2 GLU B 332 PRO B 333 0 0.02 SITE 1 AC1 16 VAL A 281 ALA A 293 LYS A 295 GLU A 310 SITE 2 AC1 16 MET A 314 ILE A 336 THR A 338 TYR A 340 SITE 3 AC1 16 MET A 341 VAL A 383 HIS A 384 ARG A 385 SITE 4 AC1 16 ALA A 403 ASP A 404 PHE A 405 HOH A1027 SITE 1 AC2 7 GLU A 517 ASP A 518 HOH A1057 HOH A1129 SITE 2 AC2 7 LYS B 427 PRO B 464 GLY B 465 SITE 1 AC3 6 LYS A 427 PRO A 464 GLY A 465 GLU B 517 SITE 2 AC3 6 ASP B 518 HOH B 571 CRYST1 42.078 63.373 74.474 78.99 89.12 90.10 P 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023765 0.000041 -0.000380 0.00000 SCALE2 0.000000 0.015780 -0.003071 0.00000 SCALE3 0.000000 0.000000 0.013681 0.00000